× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Conference Proceedings Submit Article Author Guidelines Advertise Join as Reviewer Contact Publishing Ethics


 
Year : 2017   |  Volume : 7  |  Issue : 3  |  Page : 190-193

Orlistat - an anti-obesity drug - An overview
Obesity is the fifth leading risk for international deaths. At least 2.8 million adults die per annum as a result of overweight. The current recommendations for the treatment of obesity are embraced inflated physical activity and reduced calories intake. When the activity approach is not appropriate, a medical specialty treatment is usually recommended. Most anti-obesity drugs act on central nervous system to suppress appetite and reduce food intake. In past years, varied medicine has been approved for the treatment of obesity; but, most of them are withdrawn from the market owing to their adverse effects. In fact, sibutramine licenses are withdrawn owing to an inflated risk of medical disorders and nonfatal infarct or stroke. Orlistat is presently the sole accessible selection for the treatment of obesity owing to its safety and positive effects. Orlistat, a gastric and pancreatic lipase inhibitor that reduces dietary fat absorption by approximately 30%, has been approved for use for around 10 years. It also has a positive effect on the comorbidities of obesity and has a significant effect in reducing the risk factors of cardiovascular disease and diabetes mellitus. This article focuses on the efficacy, safety, and significance of orlistat.
Print this article     Email this article

 

Contact SPER Publications


SPER Publications and Solutions Pvt. Ltd.

HD - 236,
Near The Shri Ram Millenium School,
Sector 135,
Noida-Greater Noida Expressway,
Noida-201301 [Delhi-NCR] India